These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 21829534)

  • 1. NY-ESO-1-specific circulating CD4+ T cells in ovarian cancer patients are prevalently T(H)1 type cells undetectable in the CD25+ FOXP3+ Treg compartment.
    Redjimi N; Duperrier-Amouriaux K; Raimbaud I; Luescher I; Dojcinovic D; Classe JM; Berton-Rigaud D; Frenel JS; Bourbouloux E; Valmori D; Ayyoub M
    PLoS One; 2011; 6(7):e22845. PubMed ID: 21829534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Th1/Th2 CD4+ T cell responses against NY-ESO-1 in HLA-DPB1*0401/0402 patients with epithelial ovarian cancer.
    Qian F; Gnjatic S; Jäger E; Santiago D; Jungbluth A; Grande C; Schneider S; Keitz B; Driscoll D; Ritter G; Lele S; Sood A; Old LJ; Odunsi K
    Cancer Immun; 2004 Nov; 4():12. PubMed ID: 15521719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-infiltrating T cells correlate with NY-ESO-1-specific autoantibodies in ovarian cancer.
    Milne K; Barnes RO; Girardin A; Mawer MA; Nesslinger NJ; Ng A; Nielsen JS; Sahota R; Tran E; Webb JR; Wong MQ; Wick DA; Wray A; McMurtrie E; Köbel M; Kalloger SE; Gilks CB; Watson PH; Nelson BH
    PLoS One; 2008; 3(10):e3409. PubMed ID: 18923710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MHC class II/ESO tetramer-based generation of in vitro primed anti-tumor T-helper lines for adoptive cell therapy of cancer.
    Poli C; Raffin C; Dojcinovic D; Luescher I; Ayyoub M; Valmori D
    Haematologica; 2013 Feb; 98(2):316-22. PubMed ID: 22875619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans.
    Sugiyama D; Nishikawa H; Maeda Y; Nishioka M; Tanemura A; Katayama I; Ezoe S; Kanakura Y; Sato E; Fukumori Y; Karbach J; Jäger E; Sakaguchi S
    Proc Natl Acad Sci U S A; 2013 Oct; 110(44):17945-50. PubMed ID: 24127572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD4+ T effectors specific for the tumor antigen NY-ESO-1 are highly enriched at ovarian cancer sites and coexist with, but are distinct from, tumor-associated Treg.
    Ayyoub M; Pignon P; Classe JM; Odunsi K; Valmori D
    Cancer Immunol Res; 2013 Nov; 1(5):303-8. PubMed ID: 24777968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of high and decreased NY-ESO-1 immunity to spontaneous regression and subsequent recurrence in a lung cancer patient.
    Isobe M; Eikawa S; Uenaka A; Nakamura Y; Kanda T; Kohno S; Kuzushima K; Nakayama E
    Cancer Immun; 2009 Oct; 9():8. PubMed ID: 19791734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma.
    Nicholaou T; Ebert LM; Davis ID; McArthur GA; Jackson H; Dimopoulos N; Tan B; Maraskovsky E; Miloradovic L; Hopkins W; Pan L; Venhaus R; Hoffman EW; Chen W; Cebon J
    Clin Cancer Res; 2009 Mar; 15(6):2166-73. PubMed ID: 19276262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The ratios of CD8+ T cells to CD4+CD25+ FOXP3+ and FOXP3- T cells correlate with poor clinical outcome in human serous ovarian cancer.
    Preston CC; Maurer MJ; Oberg AL; Visscher DW; Kalli KR; Hartmann LC; Goode EL; Knutson KL
    PLoS One; 2013; 8(11):e80063. PubMed ID: 24244610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD4+ CD25+ regulatory T cells control the induction of antigen-specific CD4+ helper T cell responses in cancer patients.
    Nishikawa H; Jäger E; Ritter G; Old LJ; Gnjatic S
    Blood; 2005 Aug; 106(3):1008-11. PubMed ID: 15840697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD4
    Wei Y; Yu K; Wei H; Su X; Zhu R; Shi H; Sun H; Luo Q; Xu W; Xiao J; Zhong Y; Zeng Q
    Immunology; 2017 Jul; 151(3):291-303. PubMed ID: 28207945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of regulatory T cell-resistant helper CD4+ T cells by bacterial vector.
    Nishikawa H; Tsuji T; Jäger E; Briones G; Ritter G; Old LJ; Galán JE; Shiku H; Gnjatic S
    Blood; 2008 Feb; 111(3):1404-12. PubMed ID: 17986662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overcoming regulatory T-cell suppression by a lyophilized preparation of Streptococcus pyogenes.
    Hirayama M; Nishikawa H; Nagata Y; Tsuji T; Kato T; Kageyama S; Ueda S; Sugiyama D; Hori S; Sakaguchi S; Ritter G; Old LJ; Gnjatic S; Shiku H
    Eur J Immunol; 2013 Apr; 43(4):989-1000. PubMed ID: 23436617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HLA-DP4 expression and immunity to NY-ESO-1: correlation and characterization of cytotoxic CD4+ CD25- CD8- T cell clones.
    Huarte E; Karbach J; Gnjatic S; Bender A; Jäger D; Arand M; Atanackovic D; Skipper J; Ritter G; Chen YT; Old LJ; Knuth A; Jäger E
    Cancer Immun; 2004 Dec; 4():15. PubMed ID: 15600300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of CD4+CD25+ regulatory T cells on low/high-avidity CD4+ T cells following peptide vaccination.
    Nishikawa H; Qian F; Tsuji T; Ritter G; Old LJ; Gnjatic S; Odunsi K
    J Immunol; 2006 May; 176(10):6340-6. PubMed ID: 16670346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic increase in the ratio between Foxp3+ and IL-17-producing CD4+ T cells in healthy pregnancy but not in preeclampsia.
    Santner-Nanan B; Peek MJ; Khanam R; Richarts L; Zhu E; Fazekas de St Groth B; Nanan R
    J Immunol; 2009 Dec; 183(11):7023-30. PubMed ID: 19915051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL-2 contributes to maintaining a balance between CD4+Foxp3+ regulatory T cells and effector CD4+ T cells required for immune control of blood-stage malaria infection.
    Berretta F; St-Pierre J; Piccirillo CA; Stevenson MM
    J Immunol; 2011 Apr; 186(8):4862-71. PubMed ID: 21389253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer.
    Matsuzaki J; Gnjatic S; Mhawech-Fauceglia P; Beck A; Miller A; Tsuji T; Eppolito C; Qian F; Lele S; Shrikant P; Old LJ; Odunsi K
    Proc Natl Acad Sci U S A; 2010 Apr; 107(17):7875-80. PubMed ID: 20385810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Production of NY-ESO-1 peptide/DRB1*08:03 tetramers and ex vivo detection of CD4 T-cell responses in vaccinated cancer patients.
    Mizote Y; Uenaka A; Isobe M; Wada H; Kakimi K; Saika T; Kita S; Koide Y; Oka M; Nakayama E
    Vaccine; 2014 Feb; 32(8):957-64. PubMed ID: 24397899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cord blood derived CD4+ CD25(high) T cells become functional regulatory T cells upon antigen encounter.
    Mayer E; Bannert C; Gruber S; Klunker S; Spittler A; Akdis CA; Szépfalusi Z; Eiwegger T
    PLoS One; 2012; 7(1):e29355. PubMed ID: 22272233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.